Novaliq’s dry eye disease therapy receives US FDA approval
Pharmaceutical Technology
JUNE 9, 2023
CyclASol is topical anti-inflammatory and immunomodulating ophthalmic drug solution containing 0.1% Findings from the long-term extension ESSENCE-2 OLE trial showed that CyclASol’s effect was maintained and improved for most endpoints over a treatment period of 52 weeks.
Let's personalize your content